Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Regeneron Pharmaceuticals, Inc.
< Previous
1
2
3
4
Next >
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
June 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
May 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
May 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
May 19, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
May 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
May 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports First Quarter 2023 Financial and Operating Results
May 04, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
May 02, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ALNY
REGN
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
April 17, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
April 17, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
April 11, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
April 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
March 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
March 28, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
March 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
March 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
March 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
March 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
March 14, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
March 07, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
February 28, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
February 24, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
February 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
February 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
February 08, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
February 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
January 31, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
January 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.